TABLE 4

Summary of preclinical efficacy of group III mGlu receptor allosteric modulators in schizophrenia-related deficits

Receptor	Type	Compound	Positive Symptom Models	Negative Symptoms Models	Cognitive Models	References
mGlu₄	PAM	ADX88178	Reduced NMDAR-HL; reduced DOI-induced head twitches	Reduced immobility in FST		Kalinichev et al., 2014
		Lu AF21934	Reduced NMDAR-HL and AHL;^a reduced DOI-induced head twitches^a	Reduced MK-801-induced deficits in social interaction^a	Rescued MK-801-induced deficits in the delayed spatial alternation task;^a reduced MK-801-induced deficits in NOR	(See footnotes.)
		Lu AF32615	Reduced NMDAR-HL and AHL; reduced DOI-induced head twitches	Reversed MK-801-induced deficits in social interaction	Reversed MK-801-induced deficits in the delayed spatial alternation task	Sławińska et al., 2013
mGlu₇	Ago-PAM	AMN082	No effect on AHL; exacerbated NMDAR-HL;^b exacerbated DOI-induced head twitches^c			(See footnotes.)
	NAM	MMPIP ADX71743	Inhibited MK-801-induced hyperactivity and reversed deficits in PPI		Reversed MK-801-induced deficits in NOR and spatial delayed alternation	Cieślik et al., 2018

AHL, amphetamine-induced hyperlocomotion; HL, hyperlocomotion; NOR, novel object recognition.
^aSławińska et al., 2013.
^bMitsukawa et al., 2005.
^cWierońska et al., 2012a.